Last Updated : June 21, 2022
Stereotactic ablative body radiotherapy (SABR) is a newer form of radiation treatment that delivers high doses of radiation to specific body sites over a shorter treatment period than conventional radiotherapy. For cancer therapy, including oligometastatic cancer, SABR is a non-invasive alternative to surgical treatment and an option for patients who cannot tolerate surgical procedures. However, there is a need to determine which patients should be treated with SABR to achieve the greatest benefit and how their disease should be managed. To inform decision-making on the expanded use of SABR in Canada, CADTH is undertook a Health Technology Assessment (HTA).
As part of this HTA, a clinical review was completed regarding the effectiveness and safety of SABR, with or without standard care, for the treatment of oligometastatic cancer. This review was maintained as a living systematic review for 1 year (from January 2021 to January 2022), and all versions of the report and the version history document (which details each update) are found on this page. CADTH has also undertaken an Environmental Scan of implementation considerations to further support decision-making (which can also be found on this page).